Clinical Trial Update: Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bevacizumab plus erlotinib in advanced ovarian cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• ERLOTINIB (Erlotinib)

Snippet

Sponsor: University of Arizona | Conditions: Ovarian Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2010-12-14